SOR-C13 (TFA)

SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity[1].

Product Specifications

UNSPSC

12352209

Target

TRP Channel

Type

Peptides

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sor-c13-tfa.html

Purity

99.32

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

[Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg(TFAsalt)]

Molecular Formula

C72H116N20O19.xC2HF3O2

Molecular Weight

1565.81 (free acid)

References & Citations

[1]S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35 (3) :397. |[2]Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9 (17) :3196-3207.